D. Fraughen

A randomized, double-blind, placebo-controlled trial of intravenous alpha-1 antitrypsin for ARDS secondary to COVID-19

J. Laffey, N. McElvaney, I. Martín-Loeches, 2022, Med.

Attitudes Towards Vaccination Against Coronavirus Disease 2019 in Patients with Severe Alpha-1 Antitrypsin Deficiency

N. McElvaney, B. Cleary, T. Carroll, 2022, Chronic obstructive pulmonary diseases.

Alpha-1 antitrypsin deficiency: current therapy and emerging targets

N. McElvaney, T. Carroll, O. McElvaney, 2023, Expert review of respiratory medicine.

PRE-PROOF Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation PRE-PROOF Copyright Chronic Obstructive Pulmonary Diseases: Journal of the COPD

F. Sciurba, Yingze Zhang, S. Nouraie, 2022 .

Alpha-1 antitrypsin deficiency: clarifying the role of the putative protective threshold

N. McElvaney, T. Carroll, A. Franciosi, 2021, European Respiratory Journal.

Augmentation Therapy for Severe Alpha-1 Antitrypsin Deficiency Improves Survival and Is Decoupled from Spirometric Decline—A Multinational Registry Analysis

M. Strand, B. Hobbs, G. Funk, 2023, American journal of respiratory and critical care medicine.